|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0021655,
umls-concept:C0078058,
umls-concept:C0205217,
umls-concept:C0229671,
umls-concept:C0681850,
umls-concept:C0948265,
umls-concept:C1256770,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C1749467,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-2-1
|
|
pubmed:abstractText |
Metabolic syndrome (MetS) is associated with impaired angiogenesis. Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis through binding to its specific receptor, VEGF receptor-2 (VEGFR-2), whereas the expression of VEGF and VEGFR-2 in the myocardium of insulin-resistant rats is down-regulated. Soluble VEGF receptor-1 (sVEGFR-1) and -2 (sVEGFR-2) have been reported to inhibit angiogenesis both in vitro and in vivo. However, the balance between circulating levels of VEGF and its soluble receptors, which may reflect and/or affect cardiovascular VEGF signaling, in subjects with MetS is unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1879-1484
|
|
pubmed:author |
pubmed-author:FujitaMasatoshiM,
pubmed-author:HasegawaKojiK,
pubmed-author:KawamuraTeruhisaT,
pubmed-author:KitaToruT,
pubmed-author:KitaokaShujiS,
pubmed-author:MorimotoTatsuyaT,
pubmed-author:NakanoTameoT,
pubmed-author:SatohNorikoN,
pubmed-author:ShimatsuAkiraA,
pubmed-author:WadaHiromichiH,
pubmed-author:YouW TWT
|
|
pubmed:copyrightInfo |
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
208
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
512-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19695569-Adult,
pubmed-meshheading:19695569-Cross-Sectional Studies,
pubmed-meshheading:19695569-Down-Regulation,
pubmed-meshheading:19695569-Female,
pubmed-meshheading:19695569-Humans,
pubmed-meshheading:19695569-Insulin,
pubmed-meshheading:19695569-Insulin Resistance,
pubmed-meshheading:19695569-Male,
pubmed-meshheading:19695569-Metabolic Syndrome X,
pubmed-meshheading:19695569-Middle Aged,
pubmed-meshheading:19695569-Models, Biological,
pubmed-meshheading:19695569-Myocardium,
pubmed-meshheading:19695569-Neovascularization, Pathologic,
pubmed-meshheading:19695569-Signal Transduction,
pubmed-meshheading:19695569-Vascular Endothelial Growth Factor A,
pubmed-meshheading:19695569-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance.
|
|
pubmed:affiliation |
Division of Translational Research, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan. hwada@kuhp.kyoto-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
